Teva Expects To Benefit From Consolidation Driven By "Authorized" Generics

Generic firms with smaller pipelines will feel pressure from authorized generics, CEO Makov says. Teva will not pursue a Mylan/King type of acquisition to boost its brand business because "we are doing very well in generics," the exec says.